Seeking AlphaThu, 11 Jun 2026 07:22:42 GMTIdeaya Biosciences: 'Strong Buy' On Darovasertib NDA Filing Submission Completion In H2 2026IDYA+1.43%
MarketBeatTue, 26 May 2026 23:04:00 GMTIDEAYA Biosciences Spotlights Darovasertib Win, FDA Review Path at Oncology SummitIDYA+1.43%
MarketBeatMon, 25 May 2026 11:07:58 GMTIDEAYA Biosciences Eyes Busy 2026 as Darovasertib Advances Toward FDA FilingIDYA+1.43%
MarketBeatMon, 18 May 2026 04:06:39 GMTIDEAYA Biosciences Says Melanoma Drug on Track for NDA After Strong Trial DataIDYA+1.43%
Seeking AlphaWed, 13 May 2026 02:00:50 GMTIDEAYA Biosciences, Inc. (IDYA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptIDYA+1.43%
Zacks Investment ResearchTue, 05 May 2026 12:11:08 GMTIDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue EstimatesIDYA+1.43%
Seeking AlphaMon, 13 Apr 2026 16:11:45 GMTIDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal Melanoma TranscriptIDYA+1.43%
BarronsMon, 13 Apr 2026 11:21:00 GMTIdeaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial ResultsIDYA+1.43%
